🔗 Share this article Individuals Stopping Anti-Obesity Injections Gain Back Pounds Far More Rapidly Than People Using Diet and Exercise Obesity treatment involves long-term strategies. New research reveals that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs. Findings released in a leading health publication shows that while overweight individuals can lose a large proportion of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month after stopping. "Users purchasing these drugs should be cognizant of the potential of fast rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb. This pace of regain means a return to starting weight in about 18 months. Analyzing Approaches The analysis, which looked at dozens of studies involving thousands of participants, contrasted the outcomes of these new drugs with older methods. The team point out that people who lose weight through diet and exercise generally see a slower creep back—around 100 grams monthly—once they finish. The Reason for the Rapid Regain Doctors propose the mode of action of the injections accounts for the heightened regain. GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate appetite. "Artificially providing GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist. "Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making overeating much more probable." A Lifelong Disease? The NHS recommend the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications. Many experts say that, considering the likelihood of weight regain, the therapy is often life-long. This opinion is supported by pharmaceutical companies, who say that the findings "highlight the persistent nature of excess weight," similar to managing diseases like hypertension. User Experiences Individuals who have discontinued the medication report a intense resurgence of appetite. "It was like something that goes on and you're instantly ravenous," described a patient. This challenge is exacerbated if users have not adopted lasting dietary or behavioural changes during therapy. Widespread Use Recent estimates suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand being substantial. Use is more common among females than males. The middle-aged demographic shows the highest level of interest. A large proportion obtain the drugs through private prescriptions rather than public health services. Finally, experts caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss relies on integrated lifestyle management.
Obesity treatment involves long-term strategies. New research reveals that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs. Findings released in a leading health publication shows that while overweight individuals can lose a large proportion of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month after stopping. "Users purchasing these drugs should be cognizant of the potential of fast rebound weight gain when the treatment is stopped," warns researcher Dr. Susan Jebb. This pace of regain means a return to starting weight in about 18 months. Analyzing Approaches The analysis, which looked at dozens of studies involving thousands of participants, contrasted the outcomes of these new drugs with older methods. The team point out that people who lose weight through diet and exercise generally see a slower creep back—around 100 grams monthly—once they finish. The Reason for the Rapid Regain Doctors propose the mode of action of the injections accounts for the heightened regain. GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate appetite. "Artificially providing GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist. "Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making overeating much more probable." A Lifelong Disease? The NHS recommend the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications. Many experts say that, considering the likelihood of weight regain, the therapy is often life-long. This opinion is supported by pharmaceutical companies, who say that the findings "highlight the persistent nature of excess weight," similar to managing diseases like hypertension. User Experiences Individuals who have discontinued the medication report a intense resurgence of appetite. "It was like something that goes on and you're instantly ravenous," described a patient. This challenge is exacerbated if users have not adopted lasting dietary or behavioural changes during therapy. Widespread Use Recent estimates suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand being substantial. Use is more common among females than males. The middle-aged demographic shows the highest level of interest. A large proportion obtain the drugs through private prescriptions rather than public health services. Finally, experts caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss relies on integrated lifestyle management.